https://doi.org/10.4081/cardio.2024.48
Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy
Published: November 5, 2024
Abstract Views: 1965
PDF: 483
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
Obstructive hypertrophic cardiomyopathy (oHCM) is a hereditary cardiac condition, affecting 1 in about 500 individuals, characterized by an atypical thickening of the heart muscle, specifically the interventricular septum...
Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 2018;6:364-375.
DOI: https://doi.org/10.1016/j.jchf.2018.02.010
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-33.
DOI: https://doi.org/10.1093/eurheartj/ehad637
Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep 2021;23:79.
DOI: https://doi.org/10.1007/s11886-021-01508-0
Makhija M, Bansal A, Jakhar P, Sharma L, Kumar S, Gupta D. Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy. Int J Basic Clin Pharmacol 2024;13:568-72.
DOI: https://doi.org/10.18203/2319-2003.ijbcp20241661
Yacoub MS, El-Nakhal T, Hasabo EA, et al. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev 2024;29:479-96.
DOI: https://doi.org/10.1007/s10741-023-10375-6
Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2518-32.
DOI: https://doi.org/10.1016/j.jacc.2021.09.1381
How to Cite
Shabbir, A., Yumn, L., & Khan, E. (2024). Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiology, 2(3). https://doi.org/10.4081/cardio.2024.48
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Kamilu M. Karaye, Idris Y. Mohammed, Okechukwu S. Ogah, Basil N. Okeahialam, Rationale and design for the peripartum cardiomyopathy in Nigeria (PEACE) registry , Global Cardiology: Vol. 1 No. 1 (2023)
- Stefan Peters, Encasement of the left anterior descending coronary artery: association with Takotsubo syndrome, and diagnostic and therapeutic options , Global Cardiology: Vol. 1 No. 1 (2023)
- Emanuele Monda, Giuseppe Limongelli, Unveiling the genetic aetiology of non-genetic dilated cardiomyopathy , Global Cardiology: Vol. 2 No. 4 (2024)
- Reinaldo B. Bestetti, Rosemary Furlan-Daniel, Luciano P. Pereira, COVID-19 myocarditis , Global Cardiology: Vol. 2 No. 1 (2024)
- Stephan von Haehling, Wolfram Doehner, Ruben Evertz, Tania Garfias-Veitl, Monika Diek, Mahir Karakas, Ralf Birkemeyer, Gerasimos Fillippatos, Piotr Ponikowski, Michael Böhm, Tim Friede, Stefan D. Anker, Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial , Global Cardiology: Vol. 1 No. 1 (2023)
- Kamilu M. Karaye, Abdulrazaq G. Habib, Karen Sliwa, Epidemiology of peripartum cardiomyopathy in Africa , Global Cardiology: Vol. 2 No. 2 (2024)
- Cecilia Salzillo, Lorenzo Giovannico, Giuseppe Fischetti, Gerardo Cazzato, Mario Magistro, Grazia Nucci, Gabriella Serio, Andrea Marzullo, Preliminary study on the immunohistochemical expression of galectin-3 in hypertrophic hearts , Global Cardiology: Vol. 2 No. 2 (2024)
- Rafael Vidal-Pérez, Ewa A. Jankowska, The scientific targets: the myocardium, the vasculature and the body’s response to heart failure , Global Cardiology: Vol. 2 No. 1 (2024)
- Giuseppe M.C. Rosano, Jerneja Farkas, Evolving targets for heart failure: the journey so far , Global Cardiology: Vol. 1 No. 1 (2023)
- Muhammad Shahzeb Khan, Javed Butler, Laibah Arshad Khan, Markus S. Anker, Advanced cancer as a heart failure like syndrome due to cardiac wasting cardiomyopathy: facts and numbers , Global Cardiology: Vol. 2 No. 4 (2024)
You may also start an advanced similarity search for this article.
